Correction: Limited potential of AAV-mediated gene therapy in transducing human mesenchymal stem cells for bone repair applications Gene Ther. 2024 Aug 01. . View in PubMed

Reprogramming human B cells with custom heavy-chain antibodies Nat Biomed Eng. 2024 Jul 22. . View in PubMed

Reprogramming human B cells with custom heavy chain antibodies Res Sq. 2023 Jul 17. . View in PubMed

Reprogramming human B cells with custom heavy chain antibodies bioRxiv. 2023 Jun 30. . View in PubMed

SARS-CoV-2 Enters Human Leydig Cells and Affects Testosterone Production In Vitro Cells. 2023 04 20; 12(8). . View in PubMed

Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptides J Virol. 2023 08 31; 97(8):e0068423. . View in PubMed

Knockdown of Astrocytic Monocarboxylate Transporter 4 in the Motor Cortex Leads to Loss of Dendritic Spines and a Deficit in Motor Learning Mol Neurobiol. 2022 Feb; 59(2):1002-1017. . View in PubMed

Optimization of AAV6 transduction enhances site-specific genome editing of primary human lymphocytes Mol Ther Methods Clin Dev. 2021 Dec 10; 23:198-209. . View in PubMed

Rational Selection of CRISPR-Cas9 Guide RNAs for Homology-Directed Genome Editing Mol Ther. 2021 Mar 03; 29(3):1057-1069. . View in PubMed

Limited potential of AAV-mediated gene therapy in transducing human mesenchymal stem cells for bone repair applications Gene Ther. 2021 12; 28(12):729-739. . View in PubMed

Safe and Effective In Vivo Targeting and Gene Editing in Hematopoietic Stem Cells: Strategies for Accelerating Development Hum Gene Ther. 2021 01; 32(1-2):31-42. . View in PubMed

Cytoplasmic Tail Truncation of SARS-CoV-2 Spike Protein Enhances Titer of Pseudotyped Vectors but Masks the Effect of the D614G Mutation J Virol. 2021 10 27; 95(22):e0096621. . View in PubMed

The genome-editing decade Mol Ther. 2021 11 03; 29(11):3093-3094. . View in PubMed

Genome edited B cells: a new frontier in immune cell therapies Mol Ther. 2021 11 03; 29(11):3192-3204. . View in PubMed

Reprogramming the antigen specificity of B cells using genome-editing technologies Elife. 2019 01 17; 8. . View in PubMed

Gene Editing Expands the Donor Pool for CCR5-Negative Stem Cell Transplants Cell Stem Cell. 2019 12 05; 25(6):735-736. . View in PubMed

Homologous Recombination-Based Genome Editing by Clade F AAVs Is Inefficient in the Absence of a Targeted DNA Break Mol Ther. 2019 10 02; 27(10):1726-1736. . View in PubMed

Humanized Mouse Model of HIV-1 Latency with Enrichment of Latent Virus in PD-1+ and TIGIT+ CD4 T Cells J Virol. 2019 05 15; 93(10). . View in PubMed

Reply to "Efficient Nuclease-free HR by Clade F AAV Requires High MOIs with High Quality Vectors" Mol Ther. 2019 12 04; 27(12):2061-2062. . View in PubMed

HIV-1 infection of microglial cells in a reconstituted humanized mouse model and identification of compounds that selectively reverse HIV latency J Neurovirol. 2018 04; 24(2):192-203. . View in PubMed

Inhibition of 53BP1 favors homology-dependent DNA repair and increases CRISPR-Cas9 genome-editing efficiency Nat Biotechnol. 2018 01; 36(1):95-102. . View in PubMed

Protect NIH's DNA advisory committee Science. 2018 10 26; 362(6413):409-410. . View in PubMed

Gene Therapy Approaches to Human Immunodeficiency Virus and Other Infectious Diseases Hematol Oncol Clin North Am. 2017 10; 31(5):883-895. . View in PubMed

Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression Nat Commun. 2017 03 01; 8:14447. . View in PubMed

Clinical Applications of Genome Editing to HIV Cure AIDS Patient Care STDS. 2016 12; 30(12):539-544. . View in PubMed

International AIDS Society global scientific strategy: towards an HIV cure 2016 Nat Med. 2016 08; 22(8):839-50. . View in PubMed

Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment AIDS Patient Care STDS. 2016 07; 30(7):291-306. . View in PubMed

A Cure for HIV Infection: "Not in My Lifetime" or "Just Around the Corner"? Pathog Immun. 2016; 1(1):154-164.. View in PubMed

The clinical applications of genome editing in HIV Blood. 2016 05 26; 127(21):2546-52. . View in PubMed

Preclinical development and qualification of ZFN-mediated CCR5 disruption in human hematopoietic stem/progenitor cells Mol Ther Methods Clin Dev. 2016; 3:16067. . View in PubMed

Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors Nat Biotechnol. 2015 Dec; 33(12):1256-1263. . View in PubMed

Determinants in HIV-2 Env and tetherin required for functional interaction Retrovirology. 2015 Aug 07; 12:67. . View in PubMed

Novel Arenavirus Entry Inhibitors Discovered by Using a Minigenome Rescue System for High-Throughput Drug Screening J Virol. 2015 Aug; 89(16):8428-43. . View in PubMed

Genome editing technologies: defining a path to clinic Mol Ther. 2015 May; 23(5):796-806. . View in PubMed

AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges Nature. 2015 Mar 05; 519(7541):87-91. . View in PubMed

HIV eradication--from Berlin to Boston Nat Biotechnol. 2014 Apr; 32(4):315-6. . View in PubMed

Pre-clinical modeling of CCR5 knockout in human hematopoietic stem cells by zinc finger nucleases using humanized mice J Infect Dis. 2013 Nov; 208 Suppl 2:S160-4. . View in PubMed

Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases Mol Ther. 2013 Jun; 21(6):1259-69. . View in PubMed

A systems biology starter kit for arenaviruses Viruses. 2012 Dec; 4(12):3625-46. . View in PubMed

Anti-tetherin activities of HIV-1 Vpu and Ebola virus glycoprotein do not involve removal of tetherin from lipid rafts J Virol. 2012 May; 86(10):5467-80. . View in PubMed

Substitutions in the glycoprotein (GP) of the Candid#1 vaccine strain of Junin virus increase dependence on human transferrin receptor 1 for entry and destabilize the metastable conformation of GP J Virol. 2011 Dec; 85(24):13457-62. . View in PubMed

Lack of adaptation to human tetherin in HIV-1 group O and P Retrovirology. 2011 Sep 28; 8:78. . View in PubMed

Chemokine receptor 5 knockout strategies Curr Opin HIV AIDS. 2011 Jan; 6(1):74-9. . View in PubMed

Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo Nat Biotechnol. 2010 Aug; 28(8):839-47. . View in PubMed

Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal J Virol. 2010 Jul; 84(14):7243-55. . View in PubMed

HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment Retrovirology. 2010 Jun 07; 7:51. . View in PubMed

Pseudotyping incompatibility between HIV-1 and gibbon ape leukemia virus Env is modulated by Vpu J Virol. 2010 Mar; 84(6):2666-74. . View in PubMed

Anti-tetherin activities in Vpu-expressing primate lentiviruses Retrovirology. 2010 Feb 18; 7:13. . View in PubMed

Vpu-dependent block to incorporation of GaLV Env into lentiviral vectors Retrovirology. 2010 Jan 26; 7:4. . View in PubMed

Investigation of clade B New World arenavirus tropism by using chimeric GP1 proteins J Virol. 2010 Jan; 84(2):1176-82. . View in PubMed

Stable transgene expression in primitive human CD34+ hematopoietic stem/progenitor cells, using the Sleeping Beauty transposon system Hum Gene Ther. 2009 Dec; 20(12):1607-26. . View in PubMed

Tissue-specific restriction of cyclophilin A-independent HIV-1- and SIV-derived lentiviral vectors Gene Ther. 2008 Aug; 15(15):1079-89. . View in PubMed

Receptor use by the Whitewater Arroyo virus glycoprotein Virology. 2008 Feb 20; 371(2):439-46. . View in PubMed

New world clade B arenaviruses can use transferrin receptor 1 (TfR1)-dependent and -independent entry pathways, and glycoproteins from human pathogenic strains are associated with the use of TfR1 J Virol. 2008 Jan; 82(2):938-48. . View in PubMed

Promoter choice for retroviral vectors: transcriptional strength versus trans-activation potential Hum Gene Ther. 2007 Sep; 18(9):849-60. . View in PubMed

Differences in tropism and pH dependence for glycoproteins from the Clade B1 arenaviruses: implications for receptor usage and pathogenicity Virology. 2007 Jul 20; 364(1):132-9. . View in PubMed

Receptor use by pathogenic arenaviruses Virology. 2006 Sep 15; 353(1):111-20. . View in PubMed

Recruitment of the adaptor protein 2 complex by the human immunodeficiency virus type 2 envelope protein is necessary for high levels of virus release J Virol. 2006 Mar; 80(6):2924-32. . View in PubMed

Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production J Virol. 2005 Mar; 79(6):3627-38. . View in PubMed

Cytoplasmic tail of Moloney murine leukemia virus envelope protein influences the conformation of the extracellular domain: implications for mechanism of action of the R Peptide J Virol. 2003 Jan; 77(2):1281-91. . View in PubMed

Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa Nat Genet. 2002 Dec; 32(4):670-5. . View in PubMed

Use of pseudotyped retroviral vectors to analyze the receptor-binding pocket of hemagglutinin from a pathogenic avian influenza A virus (H7 subtype) Virus Res. 2002 Feb 26; 83(1-2):43-56. . View in PubMed

Vesicular stomatitis virus G-pseudotyped lentivirus vectors mediate efficient apical transduction of polarized quiescent primary alveolar epithelial cells J Virol. 2001 Dec; 75(23):11747-54. . View in PubMed

Retroviral vectors bearing IgG-binding motifs for antibody-mediated targeting of vascular endothelial growth factor receptors Int J Mol Med. 2001 Oct; 8(4):335-43. . View in PubMed

Genomic stability of murine leukemia viruses containing insertions at the Env-3' untranslated region boundary J Virol. 2001 Aug; 75(15):6989-98. . View in PubMed

Sequences in the cytoplasmic tail of the gibbon ape leukemia virus envelope protein that prevent its incorporation into lentivirus vectors J Virol. 2001 May; 75(9):4129-38. . View in PubMed

Receptor-specific targeting mediated by the coexpression of a targeted murine leukemia virus envelope protein and a binding-defective influenza hemagglutinin protein Hum Gene Ther. 2001 Mar 01; 12(4):323-32. . View in PubMed

Identification of regions in the Moloney murine leukemia virus SU protein that tolerate the insertion of an integrin-binding peptide Virology. 2000 Mar 30; 269(1):7-17. . View in PubMed

Targeting retroviral vectors to CD34-expressing cells: binding to CD34 does not catalyze virus-cell fusion Hum Gene Ther. 1999 Mar 01; 10(4):545-57. . View in PubMed

Role of variable regions A and B in receptor binding domain of amphotropic murine leukemia virus envelope protein J Virol. 1998 Nov; 72(11):9101-8. . View in PubMed

Functional domains in the retroviral transmembrane protein J Virol. 1998 Jul; 72(7):5392-8. . View in PubMed

Characterization of the proline-rich region of murine leukemia virus envelope protein J Virol. 1998 Jul; 72(7):5383-91. . View in PubMed

Mutational analysis of the fusion peptide of Moloney murine leukemia virus transmembrane protein p15E J Virol. 1998 Feb; 72(2):1632-9. . View in PubMed

Identification of envelope protein residues required for the expanded host range of 10A1 murine leukemia virus J Virol. 1997 Nov; 71(11):8103-8. . View in PubMed

Functional analysis of the cytoplasmic tail of Moloney murine leukemia virus envelope protein J Virol. 1997 May; 71(5):3613-9. . View in PubMed

Structure-function studies of the human immunodeficiency virus type 1 matrix protein, p17 J Virol. 1997 May; 71(5):3474-83. . View in PubMed

Murine leukemia virus-based Tat-inducible long terminal repeat replacement vectors: a new system for anti-human immunodeficiency virus gene therapy J Virol. 1996 Nov; 70(11):8234-40. . View in PubMed

Conserved sequences in the carboxyl terminus of integrase that are essential for human immunodeficiency virus type 1 replication J Virol. 1996 Jan; 70(1):651-7. . View in PubMed

A transient three-plasmid expression system for the production of high titer retroviral vectors Nucleic Acids Res. 1995 Feb 25; 23(4):628-33. . View in PubMed

Human immunodeficiency virus type 1 integrase: effect on viral replication of mutations at highly conserved residues J Virol. 1994 Aug; 68(8):4768-75. . View in PubMed

Analysis of Tat function in human immunodeficiency virus type 1-infected low-level-expression cell lines U1 and ACH-2 J Virol. 1994 Mar; 68(3):1993-7. . View in PubMed

Inhibition of human immunodeficiency virus type 1 Tat-dependent activation of translation in Xenopus oocytes by the benzodiazepine Ro24-7429 requires trans-activation response element loop sequences J Virol. 1994 Jan; 68(1):25-33. . View in PubMed

Human immunodeficiency virus-1 infection of the human promyelocytic cell line HL-60: high frequency of low-level infection and effect of subsequent cell differentiation Blood. 1993 Jan 15; 81(2):437-45. . View in PubMed

Chimeric gag-V3 virus-like particles of human immunodeficiency virus induce virus-neutralizing antibodies Proc Natl Acad Sci U S A. 1992 Nov 01; 89(21):10527-31. . View in PubMed